Shares of Novavax, Inc. (NASDAQ:NVAX) have been assigned an average rating of “Hold” from the twelve brokerages that are currently covering the stock. Seven research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $5.61.
NVAX has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of Novavax from a “sell” rating to a “buy” rating and set a $1.75 target price on the stock in a report on Friday, March 3rd. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $2.00 price target on shares of Novavax in a research note on Friday, January 20th. Chardan Capital reaffirmed a “hold” rating and issued a $1.50 price target on shares of Novavax in a research note on Tuesday, February 28th. Ladenburg Thalmann Financial Services reaffirmed a “neutral” rating on shares of Novavax in a research note on Wednesday, March 1st. Finally, FBR & Co reaffirmed an “outperform” rating and issued a $12.00 price target on shares of Novavax in a research note on Wednesday, January 18th.
Novavax (NASDAQ:NVAX) traded down 0.2903% during midday trading on Monday, reaching $0.8243. 4,490,051 shares of the company traded hands. The company’s market capitalization is $223.55 million. Novavax has a one year low of $0.73 and a one year high of $8.49. The stock’s 50 day moving average is $1.22 and its 200 day moving average is $1.38.
Novavax (NASDAQ:NVAX) last issued its earnings results on Monday, February 27th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.02. Novavax had a negative net margin of 1,908.41% and a negative return on equity of 189.14%. The firm had revenue of $5.40 million for the quarter, compared to analysts’ expectations of $5.45 million. During the same quarter last year, the business earned ($0.29) earnings per share. The business’s revenue was down 7.7% on a year-over-year basis. On average, equities analysts anticipate that Novavax will post ($0.62) earnings per share for the current year.
Several institutional investors have recently modified their holdings of NVAX. Teachers Advisors LLC increased its position in shares of Novavax by 4.2% in the fourth quarter. Teachers Advisors LLC now owns 455,686 shares of the biopharmaceutical company’s stock valued at $574,000 after buying an additional 18,519 shares during the last quarter. Norges Bank bought a new position in shares of Novavax during the fourth quarter valued at $3,300,000. Perceptive Advisors LLC bought a new position in shares of Novavax during the fourth quarter valued at $423,000. Metropolitan Life Insurance Co. NY increased its position in shares of Novavax by 2.9% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 203,996 shares of the biopharmaceutical company’s stock valued at $257,000 after buying an additional 5,704 shares during the last quarter. Finally, Alden Global Capital LLC bought a new position in shares of Novavax during the fourth quarter valued at $807,000. Hedge funds and other institutional investors own 60.36% of the company’s stock.
WARNING: “Analysts Set Novavax, Inc. (NVAX) Price Target at $5.61” was originally published by WKRB News and is the property of of WKRB News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at http://www.wkrb13.com/markets/2065518/analysts-set-novavax-inc-nvax-price-target-at-5-61.html.
Novavax Company Profile
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2065518/analysts-set-novavax-inc-nvax-price-target-at-5-61.html
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.